Arvinas Inc
(NAS:ARVN)
$
25.98
1.5 (6.13%)
Market Cap: 1.79 Bil
Enterprise Value: 665.07 Mil
PE Ratio: 0
PB Ratio: 3.05
GF Score: 72/100 Arvinas Inc at Citi BioPharma Conference Transcript
Sep 08, 2022 / 05:00PM GMT
Release Date Price:
$48.42
(+6.75%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
Great. So I'm Yigal Nochomovitz, I'm one of the biotech analysts here at Citi. It's my pleasure to have with me the senior management from Arvinas Therapeutics. Sean Cassidy, CFO, welcome.
Sean A. Cassidy
Arvinas, Inc. - CFO & Treasurer
Hello.
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
Nice to see you; and Ron Peck, Chief Medical Officer.
Ronald A. Peck
Arvinas, Inc. - Chief Medical Officer
Hello.
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
Nice to see both of you.
Questions & Answers
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director
So protein degradation is obviously a super inter platform. You're one of the pioneers. There are other companies in the space too. So maybe just to level set, give us a sense for what the mission is at
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot